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Summary Case histories from 20 patients undergoing postchemotherapy "second look" laparotomy for
metastatic epithelial cell carcinoma of the ovary were reviewed in an attempt to evaluate the usefulness of this
procedure and its likely impact on patient survival. The patient population comprised 18 patients treated with
a combination of cisplatin, adriamycin and cyclophosphamide (PACe) and 2 patients treated with
chlorambucil. The findings at second look were often predictable, and related to the adequacy of initial
surgery. Complete tumour regression identified a group of patients with a relatively good prognosis. However
in most patients residual tumour was found which rarely proved resectable. Second line chemotherapy was
poorly tolerated, and appeared to have little impact on the disease particulary after combination
chemotherapy had been used initially.
There was little evidence that second look surgery itself positively contributed to survival. This procedure
and its timing should be regarded as experimental and a suitable subject for randomised clinical trials.
Metastatic epithelial cell carcinoma of the ovary
characteristically remains confined to the
abdominal cavity. The modern management of
stage III or IV disease includes bilateral salpingo-
oophorectomy, total abdominal hysterectomy
(BSO+TAH) and omentectomy at initial
exploratory surgery. In addition an attempt is made
to debulk as effectively as possible residual
metastatic disease (Griffiths 1975; Griffiths et al.,
1979). Following surgery chemotherapy is
administered either as a single agent, or more
recently as a drug combination (Young et al., 1978;
Katz et al., 1981; Williams et al., 1982). Evaluation
of tumour response during this therapy is often
difficult, and it is widely recognised that neither
clinical examination nor the radiological procedures
currently available are satisfactory to assess the
effectiveness of treatment. Second look laparotomy,
when first described in this context (Smith et al.,
1976; Schwartz & Smith, 1980) was delayed until a
complete clinical tumour remission had been
obtained after multiple courses of alkylating agent
therapy. Limitation of second look surgery to this
defined (and relatively small) population has been
associated with apparent clinical benefit; normal
findings after a scrupulous search for tumour have
predicted long term survival without further
therapy. The findings of residual tumour allowed a
change in therapy, perhaps improving survival.
More recently, and with the advent of
combination chemotherapy, second look surgery
(laparoscopy or laparotomy) has been used earlier
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in the clinical course, to date the time of complete
remission and thereby decide the number of cycles
of chemotherapy that need to be given (Young et
al., 1978; Ozols et al., 1981; Oldham et al., 1982;
Raju et al., 1982). There is, however, no evidence to
suggest that survival can be increased by use of
these techniques, and in addition only scanty
evidence exists that combination chemotherapy
produces survival that is superior to single agents
(Young et al., 1978; Katz et al., 1981; Pereira et al.,
1981; Sturgeon et al., 1982; Carmo-Pereira et al.,
1982; Vogl et al., 1982; Omura et al., 1983). We
have analysed our own experience of second look
laparotomy in an attempt to evaluate its influence
on our management of this relatively common
disorder.
Materials and methods
The study population was unselected and consisted
of patients undergoing second look laparoscopy or
laparotomy for metastatic (FIGO Stage III or IV)
epithelial cell cancer of the ovary. Initial diagnostic
laparotomies were performed by a number of
referring gynaecologists and surgeons. Where
possible bilateral salpingo-oophorectomy,
hysterectomy and omentectomy were performed,
with debulking of as much residual pelvic and
abdominal tumour as possible. Material obtained
for histology was reviewed by a reference
pathologist (Prof. D. Wright) when the initial
histologic diagnosis was confirmed, and tumour
grading performed. Patients were referred to the
Wessex Regional Oncology Unit, where
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chemotherapy administration was supervised.
Repeat laparotomy or laparoscopy was performed
by the referring gynaecologist or surgeon.
The patient population comprised two groups.
From April 1978 to May 1979 patients considered
suitable for cisplatin-containing combination
chemotherapy were treated in a pilot study with
four or five cycles of an intravenous combination,
PACe, containing cisplatin, adriamycin and
cyclophosphamide (Williams et al., 1982, vide
infra). Six patients achieving a complete clinical
remission and with a normal abdominal and pelvic
ultrasound underwent second look surgery to
evaluate response. At surgery tumour masses or
suspicious areas were biopsied and an attempt was
made, where possible, to resect completely or
debulk residual disease. Post operative chlorambucil
was given to 5 patients for a planned duration of
12 months.
From May 1979-September 1982 consenting
patients less than 70 years of age with stage III or
IV epithelial cell ovarian tumours were randomised
after initial surgery between oral chlorambucil and
the PACe combination given for 5 cycles. Clinical
examination was performed serially. Abdominal
and pelvic ultrasound examinations were obtained
prior to initial chemotherapy, and after six-twelve
months chlorambucil therapy or 5 cycles of PACe
chemotherapy. Patients achieving a complete
remission clinically and at ultrasound examination,
or those in whom the findings were equivocal, were
reviewed by the referring surgeon, with a view to
second look laparotomy. Post operative therapy
was variable. However patients in whom complete
remission was confirmed at surgery were treated
with chlorambucil for 12 months on an intermittent
schedule. Those patients achieving a partial
response or with stable disease regarded as
unresectable also in general received post operative
chlorambucil. However those patients who had
achieved a partial response after PACe
chemotherapy and in whom total tumour resection
was possible, were treated with 2 further cycles of
combination chemotherapy, followed by
chlorambucil for 12 months.
Patients were reviewed at 4 weekly intervals
whilst receiving chlorambucil, and thereafter at 2-3
monthly intervals. No further diagnostic
laparotomies were performed routinely.
Drug therapy
PACe comprised cisplatin (80mgm-2), doxorubicin
(40mgm 2) and cyclophosphamide (I gm-2) all
given i.v. on day 1 of a 28 day cycle. Cisplatin
administration was preceded by an infusion of 5%
dextrose in 1/5 normal saline given intravenously at
a rate of 500ml 2 hourly for at least 2 h, until the
urine output exceeded 150mlh -1. Cisplatin
(reconstituted in water for injection) and the other
drugs were then given by an i.v. bolus injection.
Intravenous fluids were then continued at 3 hourly
intervals until emesis stopped and the patients were
able to drink adequately. Doses of all drugs were
modified according to peripheral blood counts prior
to therapy. In addition cisplatin doses were
modified according to renal function; cisplatin was
witheld if the creatinine clearance was
<35mlmin-1, a 50% dose was given for a
clearance of 35-50mlmin-1 and a 100% dose for a
clearance >50mlmin-1.
Chlorambucil was given at a dose of 10mgday1
orally for 14 days with a fourteen day rest between
each course of treatment. Blood counts were
checked prior to each course of chlorambucil, and
appropriate dose modifications made for depression
of the white cell and platelet counts.
Tumour response evaluation
Tumour responses were recorded prior to second
look surgery (on the basis of clinical and
ultrasound examinations) and at the time of
surgery. CT scanning was not available to us at the
time of the series, and was not utilized in any
patient. Response criteria were as follows: complete
remission (CR), no clinical or radiological evidence
of disease, partial remission (PR), greater than 50%
decrease in the product of the cross sectional
diameters of the tumour, stable disease (SD), less
than 50% reduction in tumour mass, as defined,
progressive disease (PD), increase in tumour size at
any site. Equivocal CR (?CR) was a special
categorisation applied to patients with abnormal,
but biopsy negative findings at second look
laparotomy.
Survival and disease-free survival were measured
in months from the date of second look surgery.
The following coding is used in the text for
describing the present status of the patients;
A =alive without disease, A+=alive with disease,
D° =dead without known disease at the time of
death, D+=dead with disease present.
Management ofdisease relapse
Tumour relapse was documented by physical
examination and/or ultrasound. Relapse was
occasionally confirmed surgically, particularly when
associated with either a prolonged disease free
interval (and therefore potential resectability) or
intestinal obstruction.
Further therapy was given at the discretion of the
clinician, and was dependent on disease site and the
patients general condition, however, patients treated
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possible with PACe chemotherapy, as were many of
those in whom relapse from PACe occurred late.
Results
Twenty patients age range 44-68 years (mean 56)
underwent a second procedure during this four year
period. Sixteen patients were treated for FIGO
stage III and four for FIGO stage IV disease (liver
metastases 1, liver metastases and pleural effusion
1, pleural effusion only 2).
Six patients were treated with PACe before the
randomised clinical study. The remaining fourteen
patients were amongst those randomised in our
current study. Two received oral chlorabucil, and
the remaining twelve PACe induction chemotherapy
(Table I). These fourteen patients comprised 25%
of the randomised study group of 55 patients, all of
whom had completed six months therapy and were
therefore eligible for a second look procedure. A
further seven patients (13%) underwent
laparoscopy rather than laparotomy as a restaging
procedure.
Table I Chemotherapy regimens used prior to second
look procedure
1. Intermittent Chlorambucil
No. of patients 2
Duration prior to surgery 7 and 9 months
2. PACe (cisplatin, adriamycin and cyclophosphamide)
chemotherapy
No. of patients 18
PACe x 4-3 patients
PACe x 5 -6 patients
PACe+cycles omiting platinum because of toxicity-
9 patients
Cisplatin was omitted because of reduced
creatinine clearance, distressing tinnitus, or hearing
loss, from the induction PACe combination (i.e.
ACe) in one or more treatment cycles in nine of
eighteen patients (50%). Creatinine clearance was
measured serially in those patients with renal
dysfunction and cisplatin was reinstituted where
clearances improved with the aim of achieving five
cycles of treatment which included cisplatin.
The two patients treated with chlorambucil
received this drug for 7 and 9 months respectively
prior to a second look procedure.
Second look surgery. Preoperative assessment and
operativefindings
Twenty patients underwent second look laparotomy
(Table II). Preoperatively 10 patients were
Table II Preoperative assessment of patients compared
with operative findings
Clinical remission Remission status after
status second look surgery
CR ?CR PR SD PD
CR10 4 2 1 3
PR10 - 2 3 4 1
considered disease free (CR), and 10 had a
probable partial remission (PR) by virtue of either
an abnormal physical -examination or ultrasound.
Second look surgery was performed in this latter
group to confirm these findings, and where possible
to resect residual disease.
Of the 10 clinical CR patients only four proved
disease free at surgery. Two patieints were found to
have equivocal findings (?CR), one a partial
remission (PR), and 3 stable disease (SD).
Operative finds in the remaining 10 patients were
?CR 2, PR 3, SD 4 and PD 1 (Table II).
There was no significant morbidity, and no
mortality as a result of these second look
procedures. Hospital admission for laparotomy was
for 7-10 days in all cases.
In only two cases did second look surgery result
in downstaging of a patient. In one patient a mass
in the pouch of Douglas was thought to represent
tumour, although ultrasound examination was
normal. At surgery the pelvis was filled with matted
bowel with dense adhesions. No tumour was visible
(although examination was difficult) and biopsies
were negative. In the second patient the presence of
a palpable pelvic mass was confirmed by
ultrasonography. At laparotomy dense adhesions
occluded the pelvis; no tumour was visible and
biopsies were negative. These patients were
recorded as ?CR. Both have relapsed in the pelvis
at respectively 30 and 21 months after surgery, and
are alive with disease at 47 and 56 months.
Operative procedures at second look laparotomy
Definite residual disease was found in 12 of the 20
patients undergoing second look laparotomy. In
only 2 of these cases was complete tumour resection
possible. These patients had received preoperative
combination chemotherapy (PACe 5 cycles one
patient; PACe 2 cycles+ACe 7 cycles one patient).
Despite post operative chlorambucil for 1 year both
patients died of disease 12 and 29 months after
surgery.
Partial tumour resection was possible in three
patients, all of whom had received preoperative
combination chemotherapy. These 3 patients died
at 5, 7 and 9 months after second look surgery
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In the remaining 7 patients the only procedure
was biopsy of residual tumour masses.
Relationship offindings at second look surgery to
initial operative procedure
Six patients underwent successful bilateral salpingo
oophorectomy and hysterectomy at initial
exploratory surgery and 14 patients underwent
either debulking only (7 patients) or biopsy only (7
patients). (Table III). Of the 6 patients in whom
BSOH was possible 4 achieved a CR with
chemotherapy, one a ?CR and one SD. The results
in the 14 patients undergoing debulking surgery or
biopsy alone were ?CR 3, PR 4 and SD 6 and
PD 1.
Outcome ofpatients with equivocalfindings at
second look surgery (?CR)
In 4 patients the findings at second look surgery were
regarded as suspicious; however, biopsies proved
negative (Table IV). In 3 patients dense adhesions
were present throughout the abdomen, precluding a
satisfactory procedure and in one patient suspicious
areas in the pelvis proved biopsy negative. Three
patients in this group have relapsed (despite further
therapy with chlorambucil in 3) at 1, 21 and 30
months after surgery. The present status of these
patients is D +3, A+56, 47 respectively. The
remaining patient was treated with 2 cycles of ACe
chemotherapy (having received PACe x 1, ACe x 4
preoperatively) followed by chlorambucil for 1 year.
Table III Initial operative procedure and findings at second look surgery.
Assessment at
No. of Initial second look
patients procedure laparotomy Outcome+
6 BSOH CR4, ?CR 1, SD I A°8, 22D+3,
3, 15, 24
7 Debulking ?CR3, SD4 A°47, A+47, 56
only D+5, 5, 7, 18
7 Biopsy PR4, SD2, D+0, 9, 9, 12,
only PD 1 12, 22, 29
BSOH= bilateral salpingo-oophorectomy and total abdominal
hysterectomy.
+Survival and disease-free survival are given in months from the date of
second look surgery: A' =alive without disease; A+ =alive with disease;
D°=dead without known disease at the time of death and D+ =dead with
disease present.
Table IV Relationship between findings at second look surgery, post-
operative therapy and chemical outcome.
Status at Outcome (months after
second look No. of Post op second look
surgery patients therapy procedure) +
CR 4 NIL/CB/NIL/CB A°8, 22,
D+, 15, 24
?CR 4 ACE/CB/CB/CB A°47, A+47, 56, D+3
PR 4 ACe/ACe/CB/CB D+9, 9, 12, 29
SD 7 PACe/PACe/CB D+, 3, 5, 5,
ACe/CB/CB/PACe 7, 12, 18, 22
PD 1 NIL D+O
'See legend to Table III
CB =chlorambucil
ACe=adriamycin and cyclophosphamide
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She remains alive and clinically disease free 47
months post second look surgery.
Prognostic significance offindings at second look
surgery
The relationship between the findings at second
look surgery, post operative therapy and prognosis
is summarised in Table IV.
Of 16 patients with equivocal or definite disease
at surgery, only one remains clinically disease free
and 13 have died of their disease (0-29 months post
surgery, median 9 months). Within the group
achieving a CR (4 patients) two remain disease free
at 8 and 22 months. The remaining two patients
have died of disease at 15 and 24 months.
Therapy ofrelapsing or residual disease
Seventeen patients had either definite residual
disease at the time of second look surgery (12
patients) or have relapsed from a CR or ?CR (5
patients). Further therapy in these patients was
frequently prejudiced by either patient preference or
accumulated toxicity from previous chemotherapy.
Relapsefrom CRs or ?CRs (5 patients)
One patient in CR relapsed with multiple brain
metastases at 12 months. Further combination
chemotherapy was not given and the patient was
managed palliatively and died (D+ 15).
Of the remaining 4 patients 2 relapsed early (at 1
and 5 months) after PACe chemotherapy, and 2
late (27 and 30 months) after chlorambucil (1) and
PACe (1). Two of these patients have died at 3 and
24 months, and 2 are alive with disease (A+47,
56). Further combination chemotherapy proved a
problem in 2 patients because of count intolerance
(1) and patient refusal (1).
Management ofpatients with residual disease
Twelve patients were found to have residual
disease. Prior to second look surgery all of these
patients had been treated with PACe chemotherapy.
Post operatively two cycles of PACe
chemotherapy were given to 3 patients, two cycles
of ACe chemotherapy (cisplatin was precluded by a
reduced creatinine clearance) to 3 patients,
chlorambucil to 5 patients and no therapy to a
single patient who died within a month of surgery.
Chlorambucil, rather than PACe was offered to
these patients because of patient refusal to accept
PACe (1), and poor disease response despite recent
PACe (4).
Prognosis for these patients proved dismal and
all 12 patients have died of disease at 0-29 months
(median 10 months).
Discussion
Metastatic carcinoma of the ovary remains confined
to the abdominal cavity with remarkable frequency.
However this disease site is relatively inaccessible
and staging and evaluation of tumour response are
often difficult.
There are a number of theoretical advantages to
second look laparotomy. Firstly, it may provide an
opportunity to resect residual tumour masses which
have been effectively "debulked" by chemotherapy.
Secondly an abnormal second look procedure
provides a chance either to test alternative therapies
from a defined starting point or to continue
induction therapy until complete response, in the
hope that cure may still be possible. Finally a
completely normal second look procedure,
performed with scrupulous technique, provides an
opportunity either to stop therapy completely, or
test the value of consolidation or maintenance
treatment. Stopping therapy after CR may be
particularly advantageous in patients on alkylating
agents and should reduce the risk of late second
malignancy (Reimer et al., 1977; Green et al.,
1982). These advantages are, however, theoretical
and the ultimate test of the utility of this procedure
is a clinical trial.
In practice the effect of second look surgery on
patient survival has not itself been the subject of
such a trial. Instead it has been widely utilised as a
research tool, and has been recommended as a
routine procedure in the management of this
disease (Editorial, BMJ 1979).
These recommendations have been made on the
basis of retrospective studies which were not
specifically designed to test the usefulness of second
look surgery. Smith et al., (1976) and Schwartz &
Smith (1980) have the most extensive experience of
late second-look surgery in ovarian carcinoma.
Over a 14 year period (1960-1974) 142 patients
underwent second-look laparotomy. One hundred
and twenty three (87%) of these patients were
treated preoperatively with a single agent and the
majority (90%) had stage III or IV disease.
Unfortunately the authors do not provide adequate
details of the (presumably large) number of patients
with ovarian carcinoma from which this group is
derived, although in an earlier report a figure of
800 patients is given. Thirty one patients (22%)
were found to be disease free at second look
surgery and only seven of these have subsequently
relapsed, although follow up on many patients is
short. A striking relationship was found between
the number of cycles of chemotherapy given prior
to second look surgery, and the incidence of
residual disease found at surgery (14.6% negative
second look after 2-9 courses of melphalan; 43.7%
for > 10 courses of melphalan). In view of the high190 G.M. MEAD et al.
incidence of residual inoperable disease after limited
chemotherapy, and because early relapse occurred
with unacceptable frequency, they recommend a
minimum of 10 cycles of chemotherapy before
operation. This approach will, of course, select a
very small and probably atypical population of
patients who have already achieved a sustained
clinical CR to alkylating agents. The effect of
second look surgery can be judged from the finding
that only 24 of approximately 800 patients (3%)
remain in their first surgically documented
remission. Despite this, Schwartz and Smith (1980)
feel that second look surgery improves survival,
either as a result of resection or change in therapy.
The supporting evidence for this is however
inconclusive in this retrospective study.
The advent of combination chemotherapy, with
higher response rates obtained earlier in the clinical
course, had led to a re-evaluation of the role of
second look surgery. In many centres such surgery
is now performed on patients in clinical CR after
approximately six cycles of a drug combination
(Young et al., 1978; Oldham et al., 1982; Raju et
al., 1982). This provides an opportunity to resect
residual disease, continue therapy in a flexible
fashion until documented CR, or change therapy.
Oldham et al. (1982) have recently reported a study
in which a high proportion (37 of 46, 80%) of
previously untreated patients were evaluated by
second look surgery after combination
chemotherapy. The operative findings confirmed
those of many previous studies by noting a high
CR rate (88%) in those patients with initially
limited (<3cm) disease and extremely low CR rate
(10%) in all other patients. In their study 49%
(17/35) of patients with a clinical CR were found to
be in CR at surgery. A further 25% (9/35) patients
achieved a CR following surgical resection. It is,
however, notable that despite further combination
chemotherapy 4 of the 9 patients achieving a CR
by second look surgery have relapsed during a
relatively brief follow up period. Similarly Raju et
al. (1982) performed second look laparotomy in 65
patients after treatment with cisplatin or a
combination containing this drug. A quarter of
patients were found to be in CR, and prognosis in
this group proved favourable on follow up. The
majority of patients proved to have residual disease,
and debulking surgery when technically possible
appeared to have little influence on survival.
Two recent studies highlight the inadequacy of
post operative therapy in patients with residual
disease. Malcolm et al. (1983) utilised post
operative whole abdominal radiotherapy in 17
patients with minimal residual (<2cm) disease.
Fourteen of 17 patients relapsed within 8 months.
Stiff et al. (1983) treated eight patients with
minimal residual disease with a further six cycles of
a platinum-containing combination. Despite this
only one patient was rendered disease free at a
third look laparotomy.
Our experience with second look surgery is
similar to that of other groups. In a representative
patient population we have confirmed the
inaccuracy of preoperative assessment by physical
examination and ultra-sound. We have also been
able to confirm the high CR rate in patients with
minimal residual disease after initial surgery and
low CR rate in those with >3cm disease, and we
have confirmed a (relatively) good prognosis for
those patients achieving a surgically documented
CR. Downstaging as a result of surgery occurred in
only 2 patients, both of whom subsequently
relapsed with disease.
A relatively common result of these procedures,
not alluded to in the literature was that the findings
were equivocal at surgery; many patients with
initial gross tumour were found to have dense
abdominal and/or pelvic adhesions with poor
planes of cleavage and surgery proved technically
difficult. Despite negative biopsies, relapse occurred
in 4 of 5 such patients and close follow up is clearly
mandatory.
We have not been able to demonstrate any
convincing role for resection at second look
surgery, and the very poor prognosis of those
patients found to have residual disease highlights
the inefficacy of second line or alternative
chemotherapy or radiotherapy. Indeed in many
cases further therapy post surgery or at relapse was
seriously compromised by patient preference,
toxicity from initial therapy, or poor tolerance after
surgery. These data would also argue against the
use of chemotherapy to debulk tumour prior to
initial surgery.
Laparoscopy is a seemingly more attractive
procedure than laparotomy as there is less
morbidity and it can be repeated more frequently.
However it is clearly less accurate than laparotomy;
a number of centres (Smith et al., 1977; Ozols et
al., 1981) have performed laparotomy immediately
after negative laparoscopy, and have been able to
identify residual tumour in approximately 50% of
cases. A probably useful role for this procedure is a
preliminary to laparotomy. Patients with gross,
unresectable disease may then be spared formal
exploratory surgery.
We feel that early second look operations, whilst
to some extent identifying prognostic groups,
probably had little influence on therapy or on
ultimate survival. We would recommend that
routine early second laparotomy should be confined
to a clinical trial setting until a survival benefit has
been shown to result from this procedure. Trials
testing the role of early second look surgery are
needed; these should be designed to test whether aSECOND LAPAROTOMY IN OVARIAN CARCINOMA 191
second look operation in the setting of a flexible
chemotherapy regime will result in more CR's and
prolonged survival.
Those few patients on treatment who remain in
long term CR may, can be considered for second
look laparoscopy, and if this negative, laparotomy,
in an attempt to reduce the incidence of treatment
related leukaemia. Patients with residual disease
should continue with long term therapy and those
in CR can probably discountinue treatment, and be
watched carefully for disease relapse.
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